DMP — Dermapharm Holding SE Balance Sheet
0.000.00%
- €1.77bn
- €2.61bn
- €1.18bn
- 99
- 52
- 31
- 68
Annual balance sheet for Dermapharm Holding SE, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 123 | 173 | 162 | 160 | 122 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 57.8 | 84.2 | 103 | 97.9 | 112 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 400 | 519 | 534 | 630 | 593 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 200 | 222 | 226 | 331 | 315 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 1,224 | 1,407 | 1,413 | 2,161 | 2,080 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 133 | 156 | 218 | 394 | 327 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 902 | 910 | 881 | 1,621 | 1,476 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 322 | 497 | 532 | 539 | 604 |
| Total Liabilities & Shareholders' Equity | 1,224 | 1,407 | 1,413 | 2,161 | 2,080 |
| Total Common Shares Outstanding |